公开(公告)号：US20220241232A1

公开(公告)日：2022-08-04

申请号：US17617011

申请日：2020-06-08

申请人： GENFIT

发明人： JOHN BROZEK ,  NOÉMIE DAM ,  YACINE HAJJI ,  RÉMY HANF

IPC分类号： A61K31/201 ,  A61K45/06

摘要： The invention provides an anti-fibrotic or anti-nonalcoholic steatohepatitis (NASH) drug for use in a method for reducing the risk for a subject to develop liver fibrosis or NASH, wherein the drug is administered to a subject classified as at risk to develop liver fibrosis or NASH. The invention further provides an anti-fibrotic or anti-NASH substance for use in a method for the treatment of liver fibrosis or NASH, wherein the drug is administered to a subject having type 2 diabetes.